Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of Iranian made Deferasirox (Osveral®)in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study.

Autor: Eshghi, P, Farahmandinia, Z, Molavi, M, Naderi, M, Jafroodi, M, Hoorfar, H, Davari, K, Azarkeivan, A, Keikhaie, B, Ansari, S, Arasteh, M

Publikováno v: DARU: Journal of Pharmaceutical Sciences; Summer2011, Vol. 19 Issue 3, p240-248, 9p

Efficacy and safety of Iranian made Deferasirox (Osveral®)in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study

Autor: Eshghi, P., Farahmandinia, Z., Mohammad Ali Molavi, Naderi, M., Jafroodi, M., Hoorfar, H., Davari, K., Azarkeivan, A., Keikhaie, B., Ansari, S., Arasteh, M.

Publikováno v: Scopus-Elsevier
DARU : Journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Purpose of the study to determine the efficacy, adverse effects and safety of a new Iranian generic product of deferasirox (Osveral®) in Iranian transfusion dependent major thalassemic (TD-MT) patients. Methods In 9 main thalassemia treatment center

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4bb59a68735f0a597a2ea3a8f4dac7ad
http://www.scopus.com/inward/record.url?eid=2-s2.0-80053455572&partnerID=MN8TOARS

Comparison of intravenous immunoglobulin (IVIG) and intravenous anti-D for treatment of acute idiopathic thrombocytopenic purpura

Autor: Farahmandinia, Z., Naderi, A., Sabzevari, F., Saeedeh Parvaresh

Publikováno v: Scopus-Elsevier
International Journal of Hematology-Oncology and Stem Cell Research, Vol 4, Iss 4 (2010)
International Journal of Hematology-Oncology and Stem Cell Research, Vol 4, Iss 4, Pp 10-13 (2010)

"nAbstract "nIntroduction: Acute Idiopathic Thrombocytopenic purpura (ITP) is an autoimmune bleeding disorder of childhood caused by production of auto antibodies against platelets. The aim of the present study was to compare the efficacy of intraven

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::9741bcd36f410be92147a0c1c6cc8c77
http://www.scopus.com/inward/record.url?eid=2-s2.0-79961075756&partnerID=MN8TOARS